仟源医药 (300254.SZ) Stock Price, Financials & Summary | drillr

Skip to content

Sign in Sign up

Price chart

Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

19.2x

Market Cap

CNY 2.45B

MomentumView details →

1D Return

+7.43%

YTD Return

−14.03%

RSI (14)

47.7

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

19.2x

Market Cap

CNY 2.45B

RSI (14)

47.7

MomentumView details →

1D Return

+7.43%

YTD Return

−14.03%

ProfitabilityView details →

Gross Margin

66.85%

Net Margin

2.06%

EBITDA Margin

15.50%

ROE (TTM)

4.04%

ROA (TTM)

1.12%

Asset Turnover

0.53x

GrowthView details →

Revenue YoY

+2.86%

EPS YoY

−48.80%

FCF YoY

+984.67%

Revenue CAGR 3Y

+1.65%

EPS CAGR 3Y

−0.92%

EBITDA YoY

—

EarningsView details →

EPS (Actual)

—

EPS Surprise

—

Beats (12Q)

—

Next Q EPS Est

—

Avg Surprise (4Q)

—

Rev Surprise

—

Capital & dividendView details →

Debt/Equity

0.89x

Current Ratio

0.98x

Quick Ratio

0.72x

Div Yield

—

Div Rate

—

Div Growth 1Y

−60.00%

Financials snapshotView financials →

Revenue (TTM)

862.85M

Net Income (TTM)

17.80M

Op. CF (TTM)

112.71M

Latest newsMore news →

Qianyuan Pharmaceutical granted 14 million restricted shares to 49 eligible recipients on September 4, 2026, as part of its 2026 restricted stock incentive plan, with an issue price of 6.27 yuan per share.16h ago

Qianyuan Pharmaceutical announced its first-half 2026 results: net profit attributable to shareholders was 4.2858 million yuan, up 1,025.28% year-on-year, with revenue of 352 million yuan, down 5.66%.12d ago

Similar companies

北鼎股份300824.SZ *ST天箭002977.SZ 龙星科技002442.SZ 瑞尔特002790.SZ 快可电子301278.SZ 小崧股份002723.SZ Find similar companies →

Latest newsMore news →

Qianyuan Pharmaceutical granted 14 million restricted shares to 49 eligible recipients on September 4, 2026, as part of its 2026 restricted stock incentive plan, with an issue price of 6.27 yuan per share.16h ago Qianyuan Pharmaceutical announced its first-half 2026 results: net profit attributable to shareholders was 4.2858 million yuan, up 1,025.28% year-on-year, with revenue of 352 million yuan, down 5.66%.12d ago